PIN59 Cost-Effectiveness Of Becaplermin Gel On Wound Closure In The Treatment Of Pressure Ulcers  by Gilligan, A.M. & Waycaster, C.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A275
tively. Thus, conclusions from ICER and MDA assessments are consistent. To inves-
tigate the model robustness, we performed one-way and probabilistic sensitivity 
analyses. All sensitivity analyses illustrated that MDA dominated EIA and CA within 
the predefined ranges of input variables. ConClusions: Our study demonstrated 
that the routine use of MDA for CDI patients would result in substantial savings 
and improved health outcomes in US patients, compared to traditional diagnostic 
assays for this infection. These are the first data to evaluated QALY outcomes as 
they may vary with diagnostic test choice for CDI.
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objeCtives: Determine the cost-effectiveness of becaplermin gel* on wound heal-
ing for the treatment of pressure ulcers (PU). Methods: A 2-stage Markov model 
was used to predict expected costs and outcomes of wound healing for becaplermin 
gel once daily compared to placebo gel over a 1-year time period. Outcome data used 
in the analysis were derived from a 16-week randomized clinical trial. Primary out-
come of interest was ulcer-free weeks. A total of 61 patients completed the study; 31 
for becaplermin gel once-daily, and 30 for placebo gel. Patients in both arms received 
dressing changes twice daily. Patients in the treatment arm received becaplermin 
gel once daily followed by placebo gel. Transition probabilities for the Markov states 
were estimated from the clinical trial. Ulcer recurrence rates were derived from PU 
literature. Utilization for becaplermin gel was calculated using the manufacturer’s 
recommended dosing algorithm for diabetic foot ulcers. Costs were derived from 
standard cost references and medical supply wholesalers. The economic perspec-
tive taken was that of the payer. Results: Wound closure for patients treated with 
becaplermin gel was significantly (p< 0.01) higher compared to placebo gel (23% 
versus 0%, respectively) at 16 weeks. Over 1-year, patients treated with becaplermin 
gel had substantially higher ulcer-free weeks compared to placebo patients (13.5 
versus 0.0, respectively). Patients treated with becaplermin gel incurred higher total 
costs than those receiving placebo. Expected annual direct costs for PU were $3,234 
for becaplermin gel and $1,222 for placebo. The incremental cost-effectiveness ratio 
(ICER) was $149 (approximately $21/day), indicating that patients would have to pay 
an extra $149 to gain one additional ulcer-free week. ConClusions: Becaplermin 
gel was cost-effective over placebo, yielding better outcomes at a slightly higher 
cost. In addition, becaplermin gel is an effective treatment for wound healing and 
should be considered for use in the management of pressure ulcers. *Regranex®, 
Smith & Nephew Biotherapeutics, Fort Worth, Texas
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objeCtives: To determine the cost effectiveness of colistimethate sodium for 
the treatment of infections caused by multidrug-resistant (MDR). Methods: We 
compare key outcomes related to survival, infection averted and costs for infec-
tions caused by MDR. A lifetime Markov model was used to estimate the expected 
outcomes and costs for patients treated with colistimethate sodium vs non- colis-
timethate sodium group. Colistimethate sodium at a dosage of 5mg/kg/day was 
given intravenously in two divided doses. Primary outcomes were the clinical 
response and 30-day mortality; secondary outcomes were microbiological response 
and adverse events. The cost-effective analysis was conducted from the Mexican 
Health care perspective. Costs were derived from the literature, future costs and 
effects were discounted at 5% per recommendations for analyses in Mexico. All 
costs are presented in 2013 US dollars. Multiple 1-way and Probabilistic sensitivity 
analyses were performed. Results: In the colistimethate sodium group, 80.8% 
had a favorable clinical response, the overall mortality of the patients in the colis-
timethate sodium group was 46.2% and that in the non- colistimethate sodium 
group was 80%. Nephrotoxicity was found in 30.8% in the colistimethate sodium 
group. The model projects an accumulated discounted cost to the Mexican health 
care system per patient receiving the Colistimethate sodium regimen of $8,525 
compared to $7,384 for non- colistimethate sodium regimen. The base-case analy-
sis presented incremental cost-effectiveness ratios for colistimethate sodium vs 
non- colistimethate sodium grup of $ 2,213 per LYG. These values are in accordance 
with the recommendations of the Commission on Macroeconomics and Health, 
WHO, suggesting that health technologies with ICERs below the per capita GDP are 
considered very cost-effective. Results were robust to various assumptions tested 
in the sensitivity analysis. ConClusions: This study suggest that in the Mexican 
setting, use of non- colistimethate sodium for treatment of infections caused by 
MDR is likely to be cost effective.
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objeCtives: To evaluate the cost-effectiveness of micafungin compared to caspo-
fungin in the treatment of invasive Candida infection in China. Methods: A deci-
sion-tree model was developed to estimate the cost-effectiveness of micafungin and 
caspofungin from the perspective of the whole society. In the model, outcome on 
effectiveness was derived from an international, randomized, double-blind, phase III 
clinic trial and cost data was based on China’s practical situation. In the sensitivity 
analysis we use relative measurement method and absolute measurement method 
to analyze the results. Results: At the end of all antifungal therapy, the treat-
ment success rate of micafungin 100 mg/d group, micafungin 150 mg/d group and 
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objeCtives: Comparing the cost-effectiveness of Micafungin and Caspofungin for 
the treatment of systemic candida infections (including invasive candidiasis and 
candidaemia) in Switzerland. Methods: To this end, a health economic decision 
model, based on a phase-III double-blind RCT with global patient data is used. 
Hospitalization and primary medication costs are based on official Swiss data. The 
effectiveness outcome is defined as successfully treated and alive patients at the 
end of the study period. To test for robustness of cost-effectiveness results, a sub-
group analysis, a two-way sensitivity analysis and a probabilistic sensitivity analysis 
(PSA) are performed. Results: The main analysis shows that 60 % of Micafungin 
patients were successfully treated and survived at the end of study compared to 
58 % of Caspofungin patients. The costs of a Micafungin treatment (CHF 54,503) 
are smaller than the costs of a Caspofungin treatment (CHF 56,704). This results in 
a lower cost-effectiveness ratio for Micafungin (CHF 91,356) than for Caspofungin 
(CHF 98,900). Moreover, Micafungin dominates Caspofungin in the incremental cost-
effectiveness analysis. For European patients only, who can be assumed to be a more 
homogenous group and a better approximation of Swiss patients, the cost-effective-
ness ratio for Micafungin is CHF 88,474 compared to CHF 105,202 for Caspofungin. 
Two-way sensitivity analyses for both, total sample and European sub-sample, 
render Micafungin more cost-effective than Caspofungin in 20 out of 20 scenarios 
(highest incremental cost-effectiveness for Micafungin amounts to CHF 16,382). 
Probabilistic sensitivity analysis shows similar findings. ConClusions: This 
study analyzes the cost-effectiveness of Micafungin as compared to Caspofungin 
for the treatment of systemic candida infections in Switzerland. Both lower costs 
and higher effectiveness of Micafungin render Micafungin as more cost-effective 
than Caspofungin.
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objeCtives: China has experienced several severe outbreaks of influenza over the 
past century: 1918, 1957, 1968, and 2009. Influenza itself can be deadly; however, 
the increase in mortality during an influenza outbreak is also attributable to sec-
ondary bacterial infections, specifically pneumococcal disease. Given the history 
of pandemic outbreaks and the associated morbidity and mortality, we investigate 
the cost-effectiveness of a PCV7 vaccination program in China from the context of 
typical and pandemic influenza seasons. Methods: A decision-analytic model 
was employed to evaluate the impact of a 7-valent pneumococcal vaccine (PCV7) 
infant vaccination program on the incidence, mortality, and cost associated with 
pneumococcal disease during a typical influenza season and influenza pandemic in 
China. Estimates were performed comparing an 85% level of PCV7 coverage among 
all newborn infants during a single year in China relative to a case where no PCV7 
vaccinations occur for both a typical influenza season and a severe influenza pan-
demic in China. The model incorporates Chinese data where available and includes 
both direct and indirect (herd) effects on the unvaccinated population, assuming 
steady state. Costs were calculated using a payer perspective and included vac-
cination program costs and direct medical expenditures from pneumococcal dis-
ease. Results: The model predicts that PCV7 vaccination in China would prevent 
4,855,878 cases of pneumococcal disease and 66,351 deaths in a single year during a 
normal influenza season. The estimated incremental-cost-effectiveness ratios were 
¥24,383 per life-year saved and ¥25,519 per quality-adjusted-life-year gained. During 
an influenza pandemic, the model estimates that vaccination with PCV7 would 
prevent 8,192,158 cases of pneumococcal disease and 659,216 deaths, and would 
be cost-saving. ConClusions: Vaccination with PCV7 in China is cost-effective 
during typical influenza season. During an influenza pandemic, the benefit of PCV7 
in preventing excess pneumococcal morbidity and mortality renders a PCV7 vac-
cination program cost-saving.
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objeCtives: Several molecular diagnostic assays (MDA) are now commercially 
available for the diagnosis of Clostridium difficile infection (CDI). These assays detect 
genomic material associated with the pathogen’s toxin A, B and/or other genes in 
stool samples. Compared with the traditional CDI laboratory assay diagnostics, MDA 
has a shorter turn-around time and better sensitivity, but requires relatively expen-
sive instrumentation. The impact of routine use of MDA on the economics of CDI 
disease (via shorter hospitalization and less morbidity) is not clear. We evaluated 
whether routine use of MDA reduces the health care costs and improves quality-
adjusted life years (QALYs) for CDI patients. Methods: We performed a decision 
tree analysis to compare cost effectiveness of MBD with enzyme immunoassay 
(EIA) and cytotoxin assay (CA) respectively, using data from published literature 
and experts’ opinions. Analyses were conducted from the societal perspective. Both 
incremental cost-effectiveness ratio (ICER) and net monetary benefit (NMB) were 
used as criteria for evaluation. Results: The ICER shows that MDA is dominant 
to the other two alternatives. Using a base willingness-to-pay per QALY threshold 
($150,000), the NMB of MDA vs. EIA and CA are around $4,000 and $1,500, respec-
